Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $15.00 by Analysts at DA Davidson

Cellebrite DI (NASDAQ:CLBT) had its price target decreased by analysts at DA Davidson from $22.00 to $15.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. DA Davidson’s target price would suggest a potential upside of 37.17% from the company’s current price.

A number of other brokerages also recently weighed in on CLBT. Needham & Company LLC cut their price target on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating for the company in a report on Friday. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.90.

Cellebrite DI Stock Performance

Shares of CLBT stock traded up $0.14 during mid-day trading on Friday, hitting $10.94. 1,418,095 shares of the stock traded hands, compared to its average volume of 2,095,445. Cellebrite DI has a twelve month low of $9.58 and a twelve month high of $19.98. The firm has a market cap of $2.73 billion, a price-to-earnings ratio of 38.95, a price-to-earnings-growth ratio of 1.89 and a beta of 1.18. The company’s 50-day simple moving average is $14.52 and its 200-day simple moving average is $14.05.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.06. Cellebrite DI had a return on equity of 18.38% and a net margin of 14.48%.The business had revenue of $131.14 million during the quarter, compared to analyst estimates of $131.87 million. Analysts forecast that Cellebrite DI will post 0.41 earnings per share for the current year.

Insider Activity

In related news, CEO Thomas E. Hogan sold 139,713 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $15.39, for a total value of $2,150,183.07. Following the completion of the transaction, the chief executive officer owned 790,548 shares in the company, valued at $12,166,533.72. This trade represents a 15.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO David Barter sold 41,734 shares of the stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the completion of the transaction, the chief financial officer owned 334,219 shares of the company’s stock, valued at $5,474,507.22. This trade represents a 11.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 297,934 shares of company stock valued at $4,631,972 over the last three months. Insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CLBT. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its holdings in shares of Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after acquiring an additional 850 shares during the period. CWM LLC boosted its stake in Cellebrite DI by 57.0% in the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after purchasing an additional 889 shares during the period. SkyView Investment Advisors LLC boosted its stake in Cellebrite DI by 2.6% in the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after purchasing an additional 970 shares during the period. Alamea Verwaltungs GmbH grew its position in Cellebrite DI by 4.3% during the 4th quarter. Alamea Verwaltungs GmbH now owns 24,648 shares of the company’s stock worth $444,000 after purchasing an additional 1,018 shares in the last quarter. Finally, Pacer Advisors Inc. grew its position in Cellebrite DI by 45.1% during the 4th quarter. Pacer Advisors Inc. now owns 3,981 shares of the company’s stock worth $72,000 after purchasing an additional 1,238 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI News Roundup

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Cellebrite reported adjusted second-quarter EPS of $0.11, above the $0.05 consensus estimate cited by MarketBeat. Subscription revenue continued to grow, and management raised its adjusted EBITDA target. Cellebrite earnings and outlook announcement
• Positive Sentiment: Needham lowered its price target from $15.00 to $12.50 but maintained a Buy rating, implying potential upside from the current trading level. D.A. Davidson also retained its Buy rating. Needham analyst action
• Positive Sentiment: Unusually heavy call-option activity—nearly 20,000 contracts versus average volume of about 586—indicated that some traders were positioning for a rebound, although this is speculative and not a fundamental improvement.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, appointing Shiven Ramji to succeed Thomas E. Hogan. The change could support a strategic reset, but it also introduces uncertainty during a period of lowered forecasts. CEO transition announcement
• Negative Sentiment: The key reason for the selloff was the reduced outlook. Third-quarter revenue guidance of $145 million to $148 million was below the $150.3 million consensus, while full-year revenue guidance of $555 million to $561 million trailed the $568.1 million estimate. Cellebrite also lowered its full-year ARR forecast, signaling slower near-term growth. Cellebrite outlook report
• Negative Sentiment: Quarterly revenue of $131.14 million slightly missed the $131.87 million estimate. Some data providers also characterized EPS of $0.11 as below a $0.12 consensus, reinforcing concerns that the earnings beat was less important than the revenue and ARR shortfalls.
• Negative Sentiment: Multiple law firms announced investigations into possible securities-law violations and whether prior projections and disclosures were accurate. These are allegations, not established findings, but they add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his position by about 15%. The sale may be unrelated to business conditions, but its timing can weigh on investor sentiment. SEC insider sale filing

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.